Additional file 1 of Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study
These are peer-reviewed supplementary materials for the article 'COVID-19 clinical trials: who is likely to participate and why?' published in the Journal of Comparative Effectiveness Research.Appendi
*STR = WHO recommended treatment of 8 weeks streptomycin and rifampicin; #‘Category’ refers to WHO clinical severity scoring system for BU E = edematous, N = nodule, Q = Plaque, U = ulcerative.
IntroductionTo effectively manage patients with coronavirus disease 2019 (COVID-19) while minimizing contact between medical staff, clinical trial protocol that facilitates contactless patient managem
Among consecutive patients with multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia, we found those treated with ceftazidime-avibactam were more likely to develop resistance (defined as
